Inovio Pharmaceuticals (NYSE:INO) was downgraded by Zacks from an “outperform” rating to a “neutral” rating in a research report issued on Friday, StockRatingsNetwork.com reports. They currently have a $3.20 target price on the stock. Zacks‘s price target would indicate a potential upside of 26.98% from the company’s current price. Inovio Pharmaceuticals Inc (NYSEMKT:INO) shares after opening at $2.63 on last trade day and at the end of the day closed at $2.52. Company price to sales ratio in past twelve months was calculated as 44.83 and price to cash ratio as 11.51. Inovio Pharmaceuticals Inc (NYSEMKT:INO) showed a negative weekly performance of -16.00%.
Zacks cut shares of Cellcom Israel (NYSE:CEL) to a neutral rating in a research note issued to investors on Friday, Stock Ratings Network.com reports. The firm currently has $14.50 price target on the stock. Cellcom Israel Ltd. (NYSE:CEL) shares fell -0.86% in last trading session and ended the day on $13.83. CEL return on equity ratio is recorded as 49.80% and its return on assets is 3.60%. Cellcom Israel Ltd. (NYSE:CEL) yearly performance is 53.67%.
TheStreet lowered shares of Navios Maritime Acquisition Corp (NYSE:NNA) from a hold rating to a sell rating in a research report released on Friday morning, Analyst Ratings Net reports. Navios Maritime Acquisition Corp (NYSE:NNA) shares closed at $3.54 on last trading session, while trading in range of $3.52 – $3.59. Navios Maritime Acquisition Corp (NYSE:NNA) year to date (YTD) performance is -18.43%.
TheStreet cut shares of Onvia (NASDAQ:ONVI) from a hold rating to a sell rating in a research note issued to investors on Friday, American Banking News.com reports. Onvia, Inc. (NASDAQ:ONVI) weekly performance is -3.62%. On last trading day company shares ended up $5.06. Onvia, Inc. (NASDAQ:ONVI) distance from 50-day simple moving average (SMA50) is -3.62%.